Los Angeles, CA, United States of America

Roby Menefee

USPTO Granted Patents = 1 

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Roby Menefee: Innovator in Controlled Injection Technology

Introduction

Roby Menefee is an accomplished inventor based in Los Angeles, CA. He has made significant contributions to the field of controlled injection technology, particularly in medical applications. His innovative approach addresses critical needs in the treatment of dry eye syndrome.

Latest Patents

Menefee holds a patent for a "Device for controlled injection across a variety of material properties." This invention describes a generalized injection device designed to deliver formulations with various mechanical properties to precise locations. A key application of this device is the delivery of a thermally responsive hydrogel to the tear duct, aimed at treating symptoms associated with dry eye syndrome. The patent outlines methods for precise injection of low volumes, moisture retention in pre-filled devices, and options for both automatic and manual actuation.

Career Highlights

Roby Menefee is currently associated with Aesculatech, Inc., where he continues to develop innovative solutions in the medical device sector. His work focuses on enhancing the efficacy and precision of injection devices, which are crucial for various therapeutic applications.

Collaborations

Menefee collaborates with talented professionals in his field, including Niki Bayat and Adam Griese. Their combined expertise fosters a creative environment that drives innovation and advances the development of new technologies.

Conclusion

Roby Menefee's contributions to controlled injection technology exemplify the impact of innovation in medical treatments. His work not only addresses specific health challenges but also paves the way for future advancements in the field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…